BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
IDACIO (adalimumab-aacf) by Fresenius Kabi is tnf-alpha and block its interaction with the p55 and p75 cell surface tnf receptors. Approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and 4 more indications. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IDACIO (adalimumab-aacf) is a TNF-alpha inhibitor monoclonal antibody approved in December 2022 by Fresenius Kabi as a biosimilar competitor to originator adalimumab products. It treats seven inflammatory and autoimmune indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, hidradenitis suppurativa, Crohn's disease, and ulcerative colitis. The drug blocks TNF-alpha interaction with cell surface receptors, reducing pathologic inflammation and joint destruction in rheumatologic diseases and epidermal infiltration in psoriasis.
Peak
IDACIO entered a peak-stage market dominated by established TNF inhibitors and newer mechanism drugs; team focus is on differentiation through pricing and access rather than lifecycle growth.
Mechanism of Action
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is…
Indications (7)
Worked on IDACIO at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.